Serendipitous Stimulation of Nucleus Basalis of Meynert—The Effect of Unintentional, Long-Term High-Frequency Stimulation on Cognition in Parkinson’s Disease

I. Daria Bogdan 1,†, D. L. Marinus Oterdoom 1,*,‡, Teus van Laar 2, Rients B. Huijtema 2, Vincent J. Odekerken 3, Judith A. Boel 3, Rob M. A. de Bie 2, J. Marc C. van Dijk 1 and on behalf of the NSTAPS Study Group ‡

Abstract: There is a growing interest in deep brain stimulation (DBS) of the nucleus basalis of Meynert (NBM) as a potential therapeutic modality for Parkinson’s disease dementia (PDD). Low-frequency stimulation has yielded encouraging results in individual patients; however, these are not yet sustained in larger studies. With the aim to expand the understanding of NBM-DBS, we share our experience with serendipitous NBM-DBS in patients treated with DBS of the internal Globus pallidus (GPI) for Parkinson’s disease. Since NBM is anatomically located ventral to GPI, several GPI-treated patients appeared to have the distal contact of DBS-electrode(s) positioned in the NBM. We hypothesized that unintentional high-frequency NBM-DBS over a period of one year would result in the opposite effect of low-frequency NBM-stimulation and cause cognitive decline. We studied a cohort of 33 patients with bilateral high-frequency DBS in the GPI for Parkinson’s disease, of which twelve were unintentionally co-stimulated in NBM. The subgroups of unintentional unilateral (N = 7) and bilateral NBM-DBS (N = 5) were compared to the control group of bilateral GPI-DBS (N = 11). Here, we show that unintentional high-frequency NBM-DBS did not cause a significantly faster decline in cognitive function. Further research is warranted for characterizing the therapeutic role of NBM-DBS.

Keywords: Parkinson’s disease; Parkinson’s disease dementia; cognitive impairments; cognitive function; deep brain stimulation

1. Introduction

Parkinson’s disease (PD) is the fastest growing neurological disorder in the world [1]. Parkinson’s disease dementia (PDD) is diagnosed in the vast majority of PD patients during the disease course [2,3]. Clinically, PDD can be characterized as a dysexecutive syndrome with impairments in attention, executive and visuospatial functions, as well as moderately impaired memory and behavioral symptoms such as apathy and psychosis [4]. Pharmacotherapeutic options are limited to cholinesterase inhibitors and memantine and offer only modest and often non-sustained effects. Deep brain stimulation (DBS) as treatment
for cognitive decline in PDD is a subject of ongoing interest [5]. A promising target is the nucleus basalis of Meynert (NBM) due to its widespread cholinergic innervation of the cortex (for a review of the NBM functional anatomy and evidence for involvement in the cognitive decline in PDD, see Gratwicke et al., 2013) [6]. NBM holds a pivotal role in a range of cognitive functions, including those commonly affected in PDD (arousal, attention, perception, and memory) [7]. This is in line with the tight correlation observed between the extent of NBM degeneration and cortical cholinergic deficits and cognitive decline [8]. According to pilot investigations, NBM-DBS may be considered a safe procedure, without significant stimulation-induced side effects. Evidence regarding its clinical significance, however, has been equivocal (Table 1).

| Group                     | Study Design                | N  | Diagnosis | DBS Target(s) | NBM-Targeting                      | Stimulation | Outcomes                                                                 |
|---------------------------|-----------------------------|----|-----------|----------------|-----------------------------------|-------------|--------------------------------------------------------------------------|
| Freund et al., 2009 [9]   | Individual clinical trial   | 1  | PDD       | Bilateral      | Ch4 intermedius via deep           | LFS         | “Clear improvements in various aspects of cognitive functioning.”        |
|                           |                             |    |           | STN-DBS and    | frontolateral approach            | Sham        |                                                                          |
|                           |                             |    |           | NBM-DBS        |                                   |             |                                                                          |
| Kuhn et al., 2015 [10]    | RCT followed by open-label  | 6  | AD        | Bilateral      | Ch4 division of the NBM           | LFS         | “On the basis of stable/improved primary outcome parameters 12 months     |
|                           |                             |    |           | NBM-DBS        |                                   | Sham        | after surgery, 4/6 patients were considered responders.”                 |
|                           |                             |    |           |                |                                   |             |                                                                          |
| Gratwicke et al., 2018 [11]| RCT, double-blind crossover| 6  | PDD       | Bilateral      | Ch4i subsector via more posterior   | LFS         | “[ . . . ] the range of cognitive deficits were not consistently         |
|                           |                             |    |           | NBM-DBS        | entry point than used for conventional STN-DBS | Sham        | improved.”                                                               |
|                           |                             |    |           |                |                                   |             |                                                                          |
| Nombela et al., 2019 [12]| Individual clinical trial   | 1  | PD-MCI    | Bilateral      | NBM complex but not in the Ch4      | LFS         | “[ . . . ] improvements were noted in all the neuropsychological        |
|                           |                             |    |           | GPi-NBM-DBS    | intermedius                        |             | measurements except for the Categorical Verbal Fluency and Reverse Digit |
|                           |                             |    |           |                |                                   |             | Span subscale”                                                           |
|                           |                             |    |           |                |                                   |             |                                                                          |
| Gratwicke et al., 2020 [13]| RCT, double-blind crossover| 6  | DLB       | Bilateral      | Ch4i subsector via a frontal entry  | LFS         | “No consistent improvements were observed in exploratory clinical        |
|                           |                             |    |           | NBM-DBS        | point, on/posterior to the coronal suture | Sham        | outcome measures.”                                                       |
|                           |                             |    |           |                |                                   |             |                                                                          |
| Zhang et al., 2021 [14]   | Individual clinical trial   | 1  | AD        | Bilateral      | Ch4p area                          | LFS         | “Improvement in ADAS-cog, [. . . ], executive functions”, however, according to his caregiver “no substantial changes during daily life” |
|                           |                             |    |           | NBM-DBS        |                                   |             |                                                                          |

Abbreviations: AD = Alzheimer’s disease; DLB = Dementia with Lewy bodies; GPi = internal globus pallidus; LFS = low-frequency stimulation; MCI = mild cognitive impairment; NBM = nucleus basalis of Meynert; PDD = Parkinson’s disease dementia; STN = subthalamic nucleus.

Namely, while individual patients treated with low-frequency NBM-stimulation have shown encouraging results [9,10,14], larger trials yielded modest results at most [11,13]. The varied results might be attributed to several factors, including suboptimal NBM targeting, given its irregular anatomical shape [10,11] and its cytochemical heterogeneity [15]. The use of predefined stimulation parameters might have also played a detrimental role. Although the interaction of stimulation parameters with the stimulation substrate has yet to be elucidated, evidence suggests that DBS-optimization might require broad parameter searches, extending beyond the limits of conventional stimulation parameters (i.e., preset pulse-widths and frequencies) [16]. In line with this, Bergfeld and colleagues underline the
importance of first ensuring optimal DBS titration before establishing its effectivity in a randomized clinical trial of DBS for treatment-resistant depression [17]. Patient selection has also been proposed as a putative prediction factor, with recent observations suggesting that DBS may be more effective in patients with milder impairment, e.g., mild cognitive impairment or mild AD, compared to those with more advanced stages of AD [18]. Addressing these factors, although a challenging feat, will be crucial in the endeavor to establish the role of NBM-DBS in memory and cognitive deficits.

With the scope of expanding the current understanding of NBM-DBS, as well as guiding future research, we share our experience with serendipitous NBM-DBS in patients treated with GPi-DBS for PD. Since NBM is anatomically located ventrally to GPi, several GPi-treated patients turned out to have the distal contact of the DBS-electrode(s) positioned in the NBM. Here, we present the effect of unintentional, long-term high-frequency stimulation on cognition in PD. Moreover, we challenge the hypothesis that continuous, high-frequency (NBM-)stimulation would create an informational lesion [19,20] and, thus, worsen cognition [21].

2. Materials and Methods

2.1. Study Design and Participants

Between January 2007 and March 2011, 128 patients participated in The Netherlands SubThalamic and Pallidal Stimulation (NSTAPS) study. Enrollment criteria, study design, and methods are described elsewhere [22]. Following randomization, 65 patients underwent GPi-DBS (Figure 1). Seven patients did not complete the neuropsychological assessment at the 12-month follow-up. Of the remaining 58 patients, neuroimaging was available in 25 patients. To ascertain the position of the DBS electrodes, the preoperative 3T-MRI (Philips Intera, Eindhoven, The Netherlands) and post-operative CT (Sensation 64, Siemens, Erlangen, Germany) scans were merged with BrainLAB-software (BrainLAB, Heimstetten, Germany). The NBM was demarcated according to the Atlas for Stereotaxy of the Human Brain [23]. Projections of the DBS-electrode contacts were characterized as follows: (1) both electrodes solely in the GPi, no contact with NBM; (2) unilateral active contact point located inside the NBM (unilateral NBM-DBS); (3) bilateral active contact points located in the NBM (bilateral NBM-DBS). Cognitive outcomes from the neuropsychological assessment were compared between the three subgroups.

2.2. Neuropsychological Examination

All patients underwent neuropsychological examinations (NPE) during the on-drug phase at baseline and at one year after implantation, with the DBS-system switched on. NPE covered the following cognitive domains: memory, speed of information processing, attention and working memory, language, and executive functions. Verbal memory, both immediate and delayed recall, was assessed with the Dutch version of Rey’s Auditory Verbal Learning Test (AVLT) and the Rivermead Behavioural Memory Test (RBMT). For the assessment of speed of information processing, attention and working memory, the Single Choice Reaction Time Measurement of Vienna Test System (VTS-RT1), the Stroop Color-Word test (Stroop), the Trail-Making Test part A (TMT-A), and the subtest Digit Span of the Wechsler Adult Intelligence Scale III (DS) were used. The naming of words in a semantic category, as part of the Controlled Oral Word Association Test (COWAT), was used to assess semantic fluency in the language domain (COWAT-SF). Trail-Making Test part B (TMT-B) was used to assess cognitive flexibility. The naming of words starting with a specific letter, also part of the COWAT, was used to assess phonetic fluency (COWAT-PF). Raw test scores were normalized for age, gender, or education if needed and transformed to T-scores.
Figure 1. Data collection. Between January 2007 and March 2011, 128 patients participated in the NSTAPS study. Sixty-five patients were randomized to receive GPi-DBS. Since NBM is anatomically located ventral to the GPi, several GPi-treated patients appeared to have the distal contact of the DBS-electrode(s) positioned in NBM. The research database was screened for the concurrent presence of neuroimaging and neuropsychological evaluations (NPE), which were available for thirty-three GPi-DBS candidates. The positions of the DBS electrodes and active contacts were reviewed in these patients, which yielded three categories: GPi-DBS (N = 11), unilateral NBM-DBS (N = 7), and bilateral NBM-DBS (N = 5). Abbreviations: NPE = neuropsychological evaluations.

2.3. Statistical Analysis

Data were tested for normality by using the Kolmogorov–Smirnov test. The difference in cognitive performance between baseline and at 1 year after implantation was assessed between three subgroups by means of repeated-measures ANOVA (main effect group, main effect pre-post, and interaction effect group × pre-post). In order to correct for any discrepancies in the length of the follow-up interval, the number of days between two assessments was entered as covariate. Statistical analysis was performed using SPSS (SPSS IBM version 28.0, New York, NY, USA).

3. Results

3.1. Patient Characteristics and DBS Targets

Both neuroimaging and neuropsychological data were available for 33 patients (58.4 ± 7.8 years; six women). Fused MRI and CT scans were reviewed, as well as the active electrode contacts, to ascertain the DBS-target (Figure 2). Twenty-one patients were classified as receiving GPi-DBS, seven patients received unilateral NBM-DBS, and the remaining five patients were stimulated bilaterally in NBM. Patient characteristics are presented in Table 2. The three groups did not differ on any variables at baseline: age (F(2,30) = 1.371, p = 0.26); gender (χ^2(2) = 0.093, p = 0.95); disease duration (H(2) = 2.434, p = 0.29); age at diagnosis (F(2,30) = 1.06, p = 0.35); age at DBS-surgery (F(2,30) = 1.52, p = 0.23); number of days elapsed from baseline to follow-up (F(2,29) = 2.464, p = 0.103); voltage (F(2,29) = 1.29, p = 0.28); frequency (χ^2(2) = 0.06, p = 0.96); and pulse width (χ^2(2) = 1.04, p = 0.59).
Table 2. Baseline clinical characteristics of the study sample.

| Patient | Age | Gender | Disease Duration | Age at Diagnosis | Age at Surgery | Interval FU (Days) | Stimulation Parameters (Voltage, Frequency, Pulse Width) |
|---------|-----|--------|-----------------|-----------------|----------------|-------------------|------------------------------------------------------|
| PD1     | 60  | Male   | 16              | 44              | 61             | 373               | bipolar/unipolar 2.4 V, 130 Hz, 90 μs                |
| PD2     | 57  | Male   | 10              | 52              | 57             | 524               | bipolar/unipolar 2.0 V, 130 Hz, 60 μs               |
| PD3     | 63  | Male   | 10              | 54              | 64             | 483               | bipolar/unipolar 2.8 V, 130 Hz, 90 μs               |
| PD4     | 65  | Male   | 13              | 53              | 66             | 427               | unipolar/unipolar 1.8 V, 130 Hz, 60 μs              |
| PD5     | 66  | Female | 10              | 58              | 67             | 455               | bipolar/unipolar 2.8 V, 185 Hz, 60 μs               |
| PD6     | 71  | Male   | 11              | 61              | 72             | 405               | unipolar/unipolar 3.5 V, 130 Hz, 60 μs              |
| PD7     | 64  | Female | 19              | 51              | 65             | 413               | unipolar/unipolar 3.5 V, 130 Hz, 60 μs              |
| PD8     | 67  | Male   | 20              | 48              | 67             | 421               | unipolar/unipolar 3.0 V, 130 Hz, 60 μs              |
| PD9     | 60  | Male   | 9               | 51              | 60             | 472               | unipolar/unipolar 3.3 V, 130 Hz, 60 μs              |
| PD10    | 62  | Male   | 8               | 54              | 62             | 398               | bipolar/bipolar 3.0 V, 130 Hz, 60 μs               |
| PD11    | 54  | Male   | 12              | 43              | 55             | 393               | unipolar/unipolar 1.5 V, 130 Hz, 60 μs              |
| PD12    | 50  | Male   | 14              | 37              | 51             | 392               | unipolar/unipolar 3.6 V, 130 Hz, 60 μs              |
| PD13    | 61  | Female | 17              | 45              | 62             | 370               | unipolar/unipolar 2.5 V, 130 Hz, 60 μs              |
| PD14    | 58  | Male   | 14              | 44              | 58             | 360               | unipolar/bipolar 2.0 V, 130 Hz, 90 μs               |
| PD15    | 68  | Male   | 10              | 59              | 68             | 427               | bipolar/bipolar 3.5 V, 135 Hz, 90 μs               |
| PD16    | 60  | Male   | 7               | 54              | 60             | 455               | unipolar/unipolar 3.5 V, 135 Hz, 90 μs              |
| PD17    | 66  | Male   | 19              | 50              | 67             | 189               | unipolar/unipolar 2.5 V, 135 Hz, 60 μs              |
| PD18    | 54  | Male   | 11              | 45              | 55             | 428               | unipolar/unipolar 2.4 V, 135 Hz, 120 μs             |
| PD19    | 58  | Male   | 15              | 44              | 58             | 439               | unipolar/unipolar 3.0 V, 135 Hz, 90 μs              |
| PD20    | 56  | Male   | 10              | 47              | 57             | 412               | bipolar/bipolar 1.5 V, 130 Hz, 60 μs               |
| PD21    | 43  | Female | 4               | 40              | 43             | 421               | unipolar/unipolar 3.3 V, 135 Hz, 90 μs              |

Unilateral NBM-DBS N = 7

| Patient | Age | Gender | Disease Duration | Age at Diagnosis | Age at Surgery | Interval FU (Days) | Stimulation Parameters (Voltage, Frequency, Pulse Width) |
|---------|-----|--------|-----------------|-----------------|----------------|-------------------|------------------------------------------------------|
| PD22    | 69  | Male   | 10              | 59              | 69             | 573               | bipolar/bipolar 3.5 V, 185 Hz, 90 μs                |
| PD23    | 50  | Female | 8               | 42              | 50             | 457               | unipolar/unipolar 2.4 V, 130 Hz, 60 μs              |
| PD24    | 58  | Male   | 10              | 48              | 58             | 545               | bipolar/bipolar 2.0 V, 130 Hz, 60 μs               |
| PD25    | 65  | Male   | 11              | 64              | 65             | 393               | unipolar/unipolar 3.6 V, 130 Hz, 60 μs              |
| PD26    | 59  | Male   | 5               | 54              | 60             | 401               | unipolar/unipolar 3.3 V, 130 Hz, 60 μs              |
| PD27    | 36  | Male   | 7               | 30              | 37             | 364               | unipolar/unipolar 3.5 V, 130 Hz, 60 μs              |
| PD28    | 51  | Male   | 17              | 36              | 52             | 495               | bipolar/unipolar 2.8 V, 135 Hz, 60 μs               |

Bilateral NBM-DBS N = 5

| Patient | Age | Gender | Disease Duration | Age at Diagnosis | Age at Surgery | Interval FU (Days) | Stimulation Parameters (Voltage, Frequency, Pulse Width) |
|---------|-----|--------|-----------------|-----------------|----------------|-------------------|------------------------------------------------------|
| PD29    | 64  | Female | 10              | 54              | 64             | 406               | unipolar/unipolar 3.5 V, 130 Hz, 60 μs               |
| PD30    | 61  | Male   | 8               | 53              | 61             | 608               | bipolar/bipolar 3.2 V, 130 Hz, 90 μs               |
| PD31    | 46  | Male   | 11              | 35              | 46             | 385               | bipolar/bipolar 3.3 V, 130 Hz, 60 μs               |
| PD32    | 57  | Male   | 24              | 35              | 58             | unknown           | bipolar/unipolar 3.5 V, 135 Hz, 90 μs               |
| PD33    | 50  | Male   | 11              | 39              | 50             | 554               | unknown                                             |

Abbreviations: HFS = high-frequency stimulation (the stimulation frequency was 130 Hz in all patients); Interval FU = interval to follow-up (the number of days elapsed from the baseline measurements until the follow-up measurements).
3.2. Neuropsychological Outcomes

Repeated-measures ANOVA showed a significant main pre-post effect for Stroop word ($F(1,28) = 5.807; p = 0.023$), TMTA ($F(1,28) = 6.031; p = 0.02$), and TMTB/TMTA ($F(1,28) = 10.008; p = 0.004$), but no significant main effects were observed for the group on any of the variables. Most importantly, no significant interaction effect (group × pre-post) on any of the variables was found. In Table 3, mean values and $p$-values of the interaction effect are reported.

Table 3. Neuropsychological outcomes at baseline and following one year of DBS.

|                         | Baseline (PRE) | One-Year Follow-Up (POST) | $p$ Value Group × Pre-Post |
|-------------------------|----------------|---------------------------|---------------------------|
|                         | GPI-DBS        | Unilateral NBM-DBS        | Bilateral NBM-DBS         | GPI-DBS        | Unilateral NBM-DBS | Bilateral NBM-DBS |
|                         |                |                            |                           |                |                    |                     |
| AVLT immediate recall   | 48.09 ± 10.88  | 46.85 ± 11.49              | 51 ± 10.07                | 43.09 ± 9.85   | 44.85 ± 13.55      | 44.4 ± 7.82         | 0.91               |
| AVLT delayed recall (relative to IR) | 45.85 ± 9.06  | 47.42 ± 11.44              | 51 ± 7                    | 41.85 ± 11.2   | 42.42 ± 10.13      | 52.6 ± 11.67        | 0.31               |
| RBMT immediate         | 41.76 ± 13.78  | 37.14 ± 10.41              | 39.6 ± 7.82               | 38.9 ± 10.64   | 33.57 ± 7.06       | 37 ± 6.59           | 0.54               |
| RBMT delayed           | 42.47 ± 13.33  | 37.42 ± 11.63              | 48.2 ± 7.25               | 39.33 ± 10.25  | 34.8 ± 8.37        | 41.4 ± 10.01        | 0.33               |

Abbreviations: AVLT = Dutch version of Rey’s Auditory Verbal Learning Test; RBMT = Rivermead Behavioural Memory Test; VTS-RT1 = Single Choice Reaction Time Measurement of Vienna Test System; TMT A = Trail-Making Test part A; TMT B = Trail-Making Test part B; DS-WAIS III = subtest Digit Span of the Wechsler Adult Intelligence Scale III. * TMT-B also informs cognitive flexibility.

4. Discussion

In this study, we explored the post-hoc hypothesis that serendipitous high-frequency stimulation of the NBM might have a negative impact on cognitive functioning in affected subgroups. Although a general decline in some of the cognitive domains was found, no difference in decline between the GPI-stimulated and NBM-stimulated groups was observed. According to these findings, long-term high-frequency NBM-stimulation does not appear to have a negative impact on cognition in PD-patients.

A possible explanation of the lack interference with cognitive functioning could be related to the direction of targeting NBM via the GPI, which provides an almost vertical approach to the flat, disc-like structure of the NBM. This might have less influence on the NBM output than stimulation in a horizontal plane. On the other hand, diffusion-weighted imaging-based tractography (DTI) has helped refine DBS targeting and modulating white-matter tracts is increasingly favored over brain nuclei [24, 25]. So far, two studies have used DTI to track NBM cholinergic pathways [26, 27]. Both models successfully revealed tracts in both medial and lateral pathways, which is line with previous (immuno-)histochemical studies [28]. Correspondingly, a functional resting-state magnetic resonance imaging (rs-fMRI) study in healthy adult individuals revealed two distinct anterior-medial and posterior-lateral clusters [29]. Notably, the two clusters show largely different functional connectivity profiles, namely, the (1) anterior-medial cluster is connected to the hippocampus and interconnected nodes of an extended medial cortical memory network, and the
(2) posterior-lateral cluster is connected to the anterior insula and dorsal anterior cingulate components of a salience/attention network. New insights obtained by combining electrode location reconstructions and tractography studies are refining the concept of the neuromodulation substrate from the former disease-specific networks to the more focused symptom-specific networks [30]. As such, NBM-DBS might specifically require targeting the corresponding white matter tracts required to modulate memory and/or attention. Targeting NBM tracts rather than its grey matter might also be supported by the observation that (1) the coherence with the temporal region was of a smaller magnitude in the NBM region compared to outside of it and that (2) despite established connections of the NBM with many cortical regions, coherence only with the temporal region was observed inside the nucleus [31]. These pilot results might have reflected cholinergic deterioration congruent with PDD and should, thus, be interpreted accordingly. Namely, even though these findings might not support the lack of cognitive interference in our patients (who had a relatively conserved NBM-cytoarchitecture), this remains a possibly crucial consideration for surgical targeting in PDD patients. Apart from spatial targeting, the temporal specificity of the delivered neuromodulation must also be considered. For instance, delivering stimulation in phase with a rhythm may amplify it, while delivering it not-in-phase may either cancel or attenuate it [32]. To add another layer of complexity to temporal targeting, evidence suggests that different aspects of cognition may be encoded in different oscillatory frequencies [33]. Open-loop NBM-DBS may, thus, fail to interact purposefully with networks underlying memory and cognition. Novel approaches employing closed-loop neuromodulation for treatment-resistant depression [34] and enhancement of cognitive control [35] are slowly emerging and may offer valuable insights for individualizing NBM-DBS. A pressing challenge that may aid problems is identifying a biomarker for cognitive functioning, which could allow refining stimulus delivery. The latter is additionally important in light of the responsibility towards patients with implants, where “a failure to explore the many combinatorial possibilities that could still be tried, once an implanted device is already in place, seems to us a breach of the ethical doctrine of proportionality” [36,37].

5. Limitations

The fact that the NBM was not intentionally targeted might be considered a limitation of this study. Nevertheless, the position of the active contact point of the DBS-electrode in relation to the NBM was carefully assessed. Given the hitherto lack of a reliable volume of tissue activated (VTA) approximation algorithm [38], the position of the active contact was ascertained visually against the anatomical background. Although this allowed the identification of patients receiving NBM-DBS, it might not have definitely excluded patients receiving GPi-DBS, with current spread extending to the NBM. However, the observation that simultaneous GPi-NBM stimulation showed improved neuropsychological measurement in one patient with similar surgical targeting may discourage that possibility [12]. Another limitation is that we were not able to explore the effects of low-frequency stimulation in our patients. Moreover, from the limited available data, it is not possible to exclude with certainty a masked effect of NBM-DBS due to medication. Lastly, the current study is an explorative, post-hoc analysis of a subgroup of the NSTAPS-trial. As such, the study lacks a priori power analysis to confidently exclude a significant detrimental effect of high-frequency NBM-DBS. Nevertheless, by scrutinizing electrode positions of patients who underwent DBS surgery, we were able to add a considerable number of NBM-stimulated patients to the literature and, thus, expanded the knowledge on its effects.

6. Conclusions

In this post-hoc analysis of a subgroup of the NSTAPS-trial, we conclude that after one-year follow-up, unintentional high-frequency NBM-stimulation does not result in a statistically significant decline in cognitive function of PD-patients. Individualizing
patient selection, as well as the spatiotemporal coordinates of NBM-DBS, will be essential in establishing the therapeutic role of NBM-DBS in the treatment of PDD.

Author Contributions: Conceptualization: D.L.M.O., I.D.B., T.v.L., R.M.A.d.B. and J.M.C.v.D. methodology: D.L.M.O., I.D.B., R.B.H. and V.J.O.; validation: D.L.M.O., I.D.B. and R.B.H.; formal analysis: I.D.B., D.L.M.O., R.B.H., T.v.L., J.A.B., V.J.O., R.M.A.d.B. and J.M.C.v.D.; investigation: I.D.B., D.L.M.O., J.A.B. and V.J.O.; resources: J.M.C.v.D. and R.M.A.d.B.; data curation: I.D.B., D.L.M.O., and R.B.H.; writing—original draft preparation: I.D.B. and D.L.M.O.; writing—review and editing: I.D.B., D.L.M.O., T.v.L., R.B.H., V.J.O., J.A.B., R.M.A.d.B. and J.M.C.v.D.; visualization: I.D.B. and D.L.M.O.; supervision: J.M.C.v.D., R.M.A.d.B. and T.v.L.; project administration: V.J.O. and J.A.B.; funding acquisition J.A.B., V.J.O. and R.M.A.d.B. All authors have read and agreed to the published version of the manuscript.

Funding: This NSTAPS study was funded by Stichting Internationaal Parkinson Fonds, Prinses Beatrix Fonds (War05-0203), and Parkinson Vereniging (2011-V04).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of participating centers of the NSTAPS study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the NSTAPS study. Informed consent was also obtained for additional follow-up studies.

Data Availability Statement: Data are available upon request.

Conflicts of Interest: R.M.A.d.B. received a research grant from Medtronic paid to the institution. The other authors have no conflict of interest.

References
1. Dorsey, E.R.; Sherer, T.; Okun, M.S.; Bloem, B.R. The Emerging Evidence of the Parkinson Pandemic. J. Park. Dis. 2018, 8, S3–S8. [CrossRef]
2. Aarsland, D.; Kurz, M.W. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 2010, 289, 18–22. Available online: https://pubmed.ncbi.nlm.nih.gov/1973364/ (accessed on 10 July 2020). [CrossRef] [PubMed]
3. Buter, T.C.; Hout, A.V.D.; Matthews, F.E.; Larsen, J.P.; Brayne, C.; Aarsland, D. Dementia and survival in Parkinson disease: A 12-year population study. Neurology 2008, 70, 1017–1022. [CrossRef]
4. Emre, M.; Aarsland, D.; Brown, R.; Burn, D.J.; Duyckaerts, C.; Mizuno, Y.; Broe, G.A.; Cummings, J.; Dickson, D.W.; Gauthier, S.; et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. 2007, 22, 1689–1707. Available online: https://pubmed.ncbi.nlm.nih.gov/17542011/ (accessed on 11 July 2020). [CrossRef] [PubMed]
5. Turnbull, I.; McGeer, P.; Beattie, L.; Calne, D.; Pate, B. Stimulation of the Basal Nucleus of Meynert in Senile Dementia of Alzheimer’s Type. Ster. Funct. Neurosurg. 1985, 48, 216–221. [CrossRef]
6. Gratwicke, J.; Jahanshahi, M.; Foltynie, T. Parkinson’s disease dementia: A neural networks perspective. Brain 2015, 138, 1454–1476. Available online: https://academic.oup.com/brain/article/138/6/1454/2847754 (accessed on 10 July 2020). [CrossRef]
7. Gratwicke, J.; Kahan, J.; Zrinzo, L.; Hariz, M.; Limousin, P.; Foltynie, T.; Jahanshahi, M. The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia? Neurosci. Biobehav. Rev. 2013, 37, 2676–2686. [CrossRef]
8. Choi, S.H.; Jung, T.M.; Lee, J.E.; Lee, S.-K.; Sohn, Y.H.; Lee, P.H. Volumetric analysis of the substantia innominata in patients with Parkinson’s disease according to cognitive status. Neurobiol. Aging 2012, 33, 1265–1272. [CrossRef]
9. Freund, H.-J.; Kuhn, J.; Lenartz, D.; Mai, J.K.; Schnell, T.; Klosterkoetter, J.; Sturm, V. Cognitive Functions in a Patient With Parkinson-Dementia Syndrome Undergoing Deep Brain Stimulation. Arch. Neurol. 2009, 66, 781–785. [CrossRef] [PubMed]
10. Kuhn, J.; Hardenacke, K.; Lenartz, D.; Gruendlert, T.; Ullsperger, M.; Bartsch, C.; Mai, J.K.; Zilles, K.; Bauer, A.; Matusch, A.; et al. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s disease. Mol. Psychiatry 2014, 20, 353–360. [CrossRef]
11. Gratwicke, J.; Zrinzo, L.; Kahan, J.; Peters, A.; Beigi, M.; Akram, H.; Hyam, J.; Oswal, A.; Day, B.; Mancini, L.; et al. Bilateral deep brain stimulation of the nucleus basalis of Meynert for Parkinson disease dementia a randomized clinical trial. JAMA Neurol. 2018, 75, 169–178. Available online: https://pubmed.ncbi.nlm.nih.gov/29255885/ (accessed on 10 July 2020). [CrossRef]
12. Nombela, C.; Lozano, A.; Villanueva, C.; Barcia, J.A. Simultaneous Stimulation of the Globus Pallidus Interna and the Nucleus Basalis of Meynert in the Parkinson-Dementia Syndrome. Dement. Geriatr. Cogn. Disord. 2019, 47, 19–28. [CrossRef]
13. Gratwicke, J.; Zrinzo, L.; Kahan, J.; Peters, A.; Brechany, U.; McNichol, A.; Beigi, M.; Akram, H.; Hyam, J.; Oswal, A.; et al. Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimul. 2020, 13, 1031–1039. [CrossRef]
26. Liu, Q.; Zhu, Z.; Teipel, S.J.; Yang, J.; Xing, Y.; Tang, Y.; Jia, J. White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Alzheimer’s Dementia: Potential Predictors of Cognitive Change and Results of a Long-Term Follow-Up in Eight Patients. *Brain Stimul.* 2016, 9, 799–800. [CrossRef] [PubMed]

27. Nemy, M.; Cedres, N.; Grothe, M.; Muehlboeck, J.-S.; Lindberg, O.; Nedelska, Z.; Stepankova, O.; Vyslouzilova, L.; Eriksdotter, M.; et al. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. *Brain* 1998, 121, 2249–2257. Available online: https://academic.oup.com/brain/article/121/12/2249/371493 (accessed on 10 July 2020). [CrossRef]

28. Selden, N.R.; Gitelman, D.R.; Salamon-murayama, N.; Parrish, T.B.; Mesulam, M.M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. *Brain* 1998, 121, 2249–2257. Available online: https://academic.oup.com/brain/article/121/12/2249/371493 (accessed on 10 July 2020). [CrossRef]

29. Fritz, H.J.; Ray, N.; Dyrba, M.; Sorg, C.; Teipel, S.; Grothe, M.J. The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles. *Hum. Brain Mapp.* 2019, 40, 688–878. [CrossRef]

30. Tyagi, H.; Apergis-Schoute, A.M.; Akram, H.; Foltynie, T.; Limousin, P.; Drummond, L.; Fineberg, N.A.; Matthews, K.; Jahanshahi, M.; Robbins, T.W.; et al. A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects. *Biol. Psychiatry* 2019, 85, 726–734. [CrossRef]

31. Nazmuddin, M.; Oterdood, D.; van Dijk, J.M.C.; van Zijl, J.C.; Kampman, A.K.; Drost, G.; van Laar, T.; Beudel, M. Oscillatory activity and cortical coherence of the nucleus basalis of Meynert in Alzheimer’s disease dementia. *Park. Relat. Disord.* 2018, 52, 102–106. [CrossRef] [PubMed]

32. Widge, A.S.; Miller, E.K. Targeting Cognition and Networks Through Neural Oscillations: Next-Generation Clinical Brain Stimulation. *JAMA Psychiatry* 2019, 76, 671–672. Available online: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2733150 (accessed on 8 November 2021). [CrossRef]

33. Miller, E.K.; Lundqvist, M.; Bastos, A.M. Working Memory 2.0. *Neuron* 2018, 100, 463. [CrossRef] [PubMed]

34. Scangos, K.W.; Khambhati, A.N.; Daly, P.M.; Makhoul, G.S.; Sugrue, L.P.; Zamanian, H.; Liu, T.X.; Rao, V.R.; Sellers, K.K.; Dawes, H.E.; et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. *Nat. Med.* 2021, 27, 1696–1700. [CrossRef] [PubMed]

35. Basu, I.; Yousefi, A.; Crocker, B.; Zelmann, R.; Paulik, A.C.; Peled, N.; Ellard, K.K.; Weisholtz, D.S.; Cosgrove, G.R.; Deckersbach, T.; et al. Closed-loop enhancement and neural decoding of cognitive control in humans. *Nat. Biomed. Eng.* 2021, 1–13. [CrossRef]

36. Fins, J.J.; Kub, C.S.; Mayberg, H.S.; Merkel, R.; Nuttin, B.; Schlaepfer, T.E. Being open minded about neuromodulation trials: Finding success in our “failures”. *Brain Stimul.* 2017, 10, 181–186. [CrossRef] [PubMed]
37. Richardson, H.S. *Moral Entanglements: The Ancillary-Care Obligations of Medical Researchers*; Oxford University Press: Oxford, UK, 2012; Volume 253. Available online: https://books.google.com/books/about/Moral_Entanglements.html?id=2J9pAgAAQBAJ (accessed on 9 November 2021).

38. Gunalan, K.; Howell, B.; McIntyre, C.C. Quantifying axonal responses in patient-specific models of subthalamic deep brain stimulation. *NeuroImage* 2018, 172, 263–277. [CrossRef]